TIDMAGL

RNS Number : 8633F

Angle PLC

25 February 2015

 
 For immediate release    25 February 2015

ANGLE plc

("ANGLE" or "the Company")

Issue of Equity

ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, announces that it has received notice from an employee to exercise options over 166,667 ordinary shares of 10p each in the Company. Share options were issued to employees pursuant to the arrangements set out in the Company's Share Option Schemes.

Accordingly the Company has allotted 166,667 new ordinary shares of 10p each ("New Ordinary Shares") in the capital of the Company. The New Ordinary Shares rank pari passu with the existing ordinary shares in the Company. An application has been made for the New Ordinary Shares to be admitted to trading on AIM and admission is expected to take place at 8.00 am on 2 March 2015. Following this allotment, the total issued share capital of the Company is 56,583,313 ordinary shares.

For further information:

 
 ANGLE plc                           01483 685830 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
 Cenkos Securities 
  Stephen Keys, Dr Christopher 
  Golden (Nominated adviser) 
  Russell Kerr, Olly Baxendale 
  (Sales)                            020 7397 8900 
 Buchanan 
  Mark Court, Sophie Cowles          020 7466 5000

Notes for editors

About ANGLE plc

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology, known as the Parsortix system, harvests the cells of interest through a liquid biopsy, with the patient only experiencing a simple blood test. Parsortix is the subject of two granted US patents and three extensive families of patents being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the US.

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

ANGLE has established formal collaborations with world-class cancer centres and is working with these cancer centres to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy. Details are available here http://www.angleplc.com/the-company/collaborators/

In addition to cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For more information visit www.angleplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOELLFIVFDIEFIE

Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Angle Charts.